News
CBIO
16.83
-2.89%
-0.50
Weekly Report: what happened at CBIO last week (0803-0807)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO)
TipRanks · 08/04 02:10
Weekly Report: what happened at CBIO last week (0727-0731)?
Weekly Report · 08/03 09:39
Crescent Biopharma Announces Grants of Inducement Awards
Barchart · 08/03 06:30
Crescent Biopharma (CBIO) Gets a Buy from Wedbush
TipRanks · 07/31 15:48
Analysts Offer Insights on Healthcare Companies: Pasithea Therapeutics Corp (KTTA), Crescent Biopharma (CBIO) and Dexcom (DXCM)
TipRanks · 07/31 10:30
Analyst Backs Crescent Biopharma With Buy Rating on Advancing ADC Pipeline and Strong Cash Runway
TipRanks · 07/30 20:35
Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate
Benzinga · 07/30 12:14
Crescent Biopharma reports Q2 EPS (74c), consensus (64c)
TipRanks · 07/30 12:00
*Crescent Biopharma 2Q Research and Development Expenses $19.4M >CBIO
Dow Jones · 07/30 11:35
*Crescent Biopharma 2Q Loss/Shr 74c >CBIO
Dow Jones · 07/30 11:35
Press Release: Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Dow Jones · 07/30 11:35
Press Release: Crescent Biopharma Reports Second -2-
Dow Jones · 07/30 11:35
Crescent Biopharma: Q2 Earnings Snapshot
Barchart · 07/30 06:43
Weekly Report: what happened at CBIO last week (0720-0724)?
Weekly Report · 07/27 09:41
Travelers, TransDigm, Cytokinetics, Global-e, Crescent Shock Moves
TipRanks · 07/25 13:01
Crescent Biopharma Announces Grants of Inducement Awards
Barchart · 07/23 15:15
Fourteen new option listings and one option delisting on July 22nd
TipRanks · 07/22 12:30
Major Investor Makes Bold Move on Crescent Biopharma Shares
TipRanks · 07/21 02:01
Weekly Report: what happened at CBIO last week (0713-0717)?
Weekly Report · 07/20 09:39
More
Webull provides a variety of real-time CBIO stock news. You can receive the latest news about Crescent Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About CBIO
Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.